The Greater Houston Partnership hosted its annual economic outlook event online — here's what the numbers indicate for Houston business in the new year. Photo via Getty Images

As much of the world is ready to celebrate a new year — one likely to be drastically less affected by COVID-19 — the Greater Houston Partnership released an annual report about what Houston's economy will look like in 2021.

Senior vice president of research Patrick Jankowski and his team put the Houston Region Economic Outlook report together and shared some its highlights at a virtual event hosted by Bob Harvey, president and CEO of GHP.

Of course, much of the study focused on how the coronavirus — as well as the impending vaccine — will affect the region's economy.

"At this point last year, neither Patrick nor any of us could have predicted the arrival of COVID-19 and its devastating impact on the global economy," Harvey says at the event. "Here in Houston COVID wreaked havoc on industries across the spectrum from energy to hospitality."

In the early weeks, the Houston region lost 350,000 jobs, according to the report, and in the months since, the region added back about half with 176,000 jobs.

Below are some more key takeaways from the report — and in most cases, the outcome depends on how COVID-19 case numbers are affected by the holidays and the accessibility of the vaccine.

"The weeks and months ahead are likely to be some of the most difficult of the pandemic," Harvey cautions. "We cannot afford to let our guard down now as we approach the finish line."

Energy will continue to struggle

Photo via Getty Images

The past six years have been rough for oil and gas, and in Houston specifically, Houston has lost nearly 100,000 upstream energy jobs, and the energy industry's share of Houston's GDP has fallen from 35 to 40 percent (a GHP '14 estimate) to 20 to 25 percent (a GHP '19 estimate).

The Russia-Saudi Oil Feud in March brought this decline to its head and it's not looking like it's getting back to normal any time soon. "Next year won't be any easier for the industry. While global demand has improved, it will remain three to five million barrels per day below pre-COVID levels," reads the report.

The new administration is expected to have several goals that will affect the industry, such as bringing the U.S. back into the Paris Agreement, negotiating new mileage and emission rules for autos and trucks, slowing or halting oil leasing on federal lands and in the Gulf of Mexico, increasing environmental scrutiny during the pipeline permitting process, and more.

Jobs in some industries will come back

Chart via GHP

According to the report, Houston's unemployment rate, at 3.9 percent in February, jumped to 5.5 percent in March, then 14.3 percent in April — the highest on record.

"Unemployment has improved — we're at 7.9 percent now," Jankowski says at the event.

But recovery depends on the industry. Jankowski predicts that retail and energy are both expected to continue to lose jobs, and other industry sectors — such as government, arts and entertainment, and educational services — aren't expected to grow by much.

However, some of the sectors hardest hit in 2020 — construction, manufacturing, support services, and restaurants — are expected to bounce back with thousands of new jobs.

The chart gives a range of job growth — there's a lower and a higher outlook. Jankowski says it depends on how well the vaccine is doing.

If by mid-year, we don't have much of the population inoculated, it's going to be closer to that lower number," he says.

2021 will be a "bipolar year"

Patrick Jankowski of the GHP. Photo via Houston.org

The first and second halves of the year are going to look different, Jankowski says, it's just a matter of how different at this point. In addition to the vaccine and COVID case numbers, the things the GHP as well as Houston businesses are watching is the new Biden Administration

"We won't see any significant growth in the economy until we get to the second half of the year," he says

The first quarter of 2021 will be especially tough for Houston, according to the report, since the region always experiences job losses in January as retail, restaurant, and transportation workers hired for the holiday season are rolled off. Additionally, contract workers employed to meet year-end deadlines are released and plans for reorganization are implemented.

"No one should be surprised when Houston loses 40,000 or more jobs this January," the report reads. "Houston's recovery will likely lag the U.S.'s by a few months, but growth will resume in the second half of '21."

Three panelists representing the real estate, banking, and health care industries weighed in on innovation in Houston. Photo via Greater Houston Partnership/Facebook

Overheard: Houston execs weigh in on the innovation ecosystem and local startups

Eavesdropping in Houston

Something has shifted in Houston, and businesses across industries — whether it be real estate, health care, or energy — are focused on innovation, emerging technologies, and the role of startups within the business community.

At the Greater Houston Partnership's annual Economic Outlook on December 5, three panelists from various industries gathered to discuss some of the biggest issues in Houston — from the multifamily real estate market to what the local workforce needs. The panel was moderated by Eddie Robinson, the morning news anchor for Houston Public Radio, and the panelists did weigh in a few issues affecting innovation.

Missed the talk? Here are a few overheard moments from the discussion.

"Houston allows you to do what you do. And you don't get that in other places."

Photo via Greater Houston Partnership/Facebook

Bradley R. Freels, chairman of Midway Cos. Freels says, while the city's been overshadowed by other Texas cities for innovation and tech — and even by its large oil and gas industry presence, the city is becoming a great place for startups. "This is a great place to do business because it's easy to get started in business here. I think it's just over shadowed to some degree," he says, adding later that, "the initiative around the innovation corridor is real."

"Houston is unique, in my opinion, in how open and welcoming it is."

Photo via Greater Houston Partnership/Facebook

— David Milich, CEO of UnitedHealthcare - Texas & Oklahoma. Building off the panelists point that Houston is a spirited, can-do city, Milich specifies that it's the collaboration between people in Houston that sets the city apart. "When we present ourselves with something to get done, we generally get it down."

"We're realizing that the economy is shifting. As we move forward in the 21st century, our entire workforce needs to be tech fluent."

Photo via Greater Houston Partnership/Facebook

Nataly Marks, managing director and region manager at JPMorgan Chase. When asked about jobs needed in Houston, Marks specified technology positions. Moreover, JPMorgan Chase is emphasizing getting the entire staff proficient in the latest tech resources.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.